Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 11/20 | 0.51 |
| ▸ | LTB4R2 | Q9NPC1 | 11/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3104 | 0.99 | AGTR1 (0.50) | AGTR1LTB4R2ABCB11GP6 | |
| Abitesartan SCHEMBL8473295 | 0.95 | AGTR1 (0.47) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL8482137 | 0.92 | AGTR1 (0.43) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL7270763 | 0.92 | AGTR1 (0.47) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2864 | 0.92 | AGTR1 (0.47) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL8483446 | 0.91 | AGTR1 (0.43) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL682687 | 0.91 | AGTR1 (0.47) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2959 | 0.90 | AGTR1 (0.47) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL8912327 | 0.90 | AGTR1 (0.41) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2967 | 0.90 | AGTR1 (0.46) | AGTR1LTB4R2ABCB11GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 933 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082608-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2025-03-13 | — | — | US | claimed |
| EP-4448096-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | Singapore Health Services Pte. Ltd. (SG) | 2024-10-23 | — | — | EP | claimed |
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | claimed |
| US-11851443-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-12-26 | — | — | US | claimed |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | claimed |
| US-11718591-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-08 | — | — | US | claimed |
| WO-2023111196-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE. LTD. (SG) | 2023-06-22 | — | — | WO | claimed |
| US-11634413-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-04-25 | — | — | US | claimed |
| US-20220298173-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-22 | — | — | US | claimed |
| US-20220242836-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-08-04 | — | — | US | claimed |
| CN-1259912-C | Citalopram for the treatment of elevated blood pressure | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2006-06-21 | — | — | CN | claimed |
| EP-1667643-A2 | NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2006000564-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NEP-INHIBITORS, INHIBITORS OF THE ENDOGENOUS ENDOTHELIN PRODUCING SYSTEM AND AT1-RECEPTOR ANTAGONISTS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-01-05 | — | — | WO | claimed |
| US-20050288272-A1 | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-12-29 | — | — | US | claimed |
| EP-1545540-A2 | COMBINATION THERAPY USING A DUAL PPAR ALPHA/GAMMA AGONIST AND AN ANGIOTENSIN II TYPE I RECEPTOR ANTAGONIST | Merck & Co., Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| WO-2005023182-A2 | NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-03-17 | — | — | WO | claimed |
| CN-1568183-A | Citalopram for the treatment of elevated blood pressure | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2005-01-19 | — | — | CN | claimed |
| WO-2004017896-A2 | COMBINATION THERAPY USING A DUAL PPAR ALPHA/GAMMA AGONIST AND AN ANGIOTENSIN II TYPE I RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 2004-03-04 | — | — | WO | claimed |
| EP-0443983-B1 | Acyl compounds | CIBA GEIGY AG (CH) | 1996-02-28 | — | — | EP | claimed |
| EP-0443983-A1 | Acyl compounds | CIBA-GEIGY AG (CH) | 1991-08-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | AGTR1 5/4885LTB4R2 1129/4885ABCB11 521/4885 |
| US-11718591-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof | MME, CTSC, REN | AGTR1 25/4885LTB4R2 1763/4885ABCB11 2451/4885 |
| US-20220242836-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | MME, CTSC, REN | AGTR1 25/4885LTB4R2 1817/4885ABCB11 2504/4885 |
| US-20050288272-A1 | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists | ECE1, EDNRA, MME | AGTR1 6/4885LTB4R2 834/4885ABCB11 1292/4885 |
| US-11634413-B2 | Neprilysin inhibitors | MME, REN, ACE | AGTR1 4/4885LTB4R2 1401/4885ABCB11 947/4885 |
| US-20220298173-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | AGTR1 4/4885LTB4R2 1108/4885ABCB11 468/4885 |
| US-11851443-B2 | Neprilysin inhibitors | MME, REN, ACE | AGTR1 4/4885LTB4R2 1136/4885ABCB11 507/4885 |
| US-12016835-B2 | Neprilysin inhibitors | MME, REN, ACE | AGTR1 5/4885LTB4R2 1129/4885ABCB11 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.